SynergyX: a multi-modality mutual attention network for interpretable drug synergy prediction

Yue Guo,Haitao Hu,Wenbo Chen,Hao Yin,Jian Wu,Chang-Yu Hsieh,Qiaojun He,Ji Cao

DOI: https://doi.org/10.1093/bib/bbae015

IF: 9.5

2024-02-11

Briefings in Bioinformatics

Abstract:Discovering effective anti-tumor drug combinations is crucial for advancing cancer therapy. Taking full account of intricate biological interactions is highly important in accurately predicting drug synergy. However, the extremely limited prior knowledge poses great challenges in developing current computational methods. To address this, we introduce SynergyX, a multi-modality mutual attention network to improve anti-tumor drug synergy prediction. It dynamically captures cross-modal interactions, allowing for the modeling of complex biological networks and drug interactions. A convolution-augmented attention structure is adopted to integrate multi-omic data in this framework effectively. Compared with other state-of-the-art models, SynergyX demonstrates superior predictive accuracy in both the General Test and Blind Test and cross-dataset validation. By exhaustively screening combinations of approved drugs, SynergyX reveals its ability to identify promising drug combination candidates for potential lung cancer treatment. Another notable advantage lies in its multidimensional interpretability. Taking Sorafenib and Vorinostat as an example, SynergyX serves as a powerful tool for uncovering drug-gene interactions and deciphering cell selectivity mechanisms. In summary, SynergyX provides an illuminating and interpretable framework, poised to catalyze the expedition of drug synergy discovery and deepen our comprehension of rational combination therapy.

biochemical research methods,mathematical & computational biology

What problem does this paper attempt to address?

The paper aims to address the challenges in predicting anticancer drug combinations, particularly how to accurately predict drug synergy in the absence of sufficient prior knowledge. To tackle this issue, the research team proposed a new model named SynergyX. SynergyX is a multi-modality mutual attention network that can dynamically capture cross-modality interactions, thereby modeling complex biological networks and drug interactions. The model employs a convolution-enhanced attention structure to effectively integrate multi-omics data and has demonstrated superior predictive accuracy in multiple benchmarks. Additionally, SynergyX possesses multi-dimensional interpretability, capable of revealing interactions between drugs and genes as well as cell selectivity mechanisms. By screening combinations of approved drugs, SynergyX has shown its potential in identifying candidate drug combinations for lung cancer treatment. In summary, SynergyX provides an insightful and interpretable framework that is expected to accelerate the drug synergy discovery process and deepen the understanding of rational combination therapies.